{"nctId":"NCT02831660","briefTitle":"CU Programme of Idarucizumab for Japanese Patients","startDateStruct":{"date":"2016-07-22","type":"ACTUAL"},"conditions":["Hemorrhage"],"count":1,"armGroups":[{"label":"idarucizumab","type":"EXPERIMENTAL","interventionNames":["Drug: idarucizumab"]}],"interventions":[{"name":"idarucizumab","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Currently taking dabigatran etexilate.\n* Age \\>= 20 years at entry.\n* Written Informed consent\n* Group A:\n\n  \\-- Uncontrolled or life-threatening judged by the physician to require a reversal agent.\n* Group B:\n\n  * A condition requiring emergency surgery or invasive procedure where adequate hemostasis is required. Emergency is defined as within the following 8 hours.\n\nExclusion criteria:\n\n* Contraindications to study medication including known hypersensitivity to the drug or its excipients (subjects with hereditary fructose intolerance may react to sorbitol).\n* Group A:\n\n  * Patients with minor bleeding (e.g. epistaxis, hematuria) who can be managed with standard supportive care.\n  * Patients with no clinical signs of bleeding.\n* Group B:\n\n  * surgery or procedure which is elective or where the risk of uncontrolled or unmanageable bleeding is low.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Subjects With Drug-related Adverse Events","description":"Percentage of subjects with drug-related adverse events is presented","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":1},"commonTop":["Platelet count decreased"]}}}